Calquence is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...

With cancer therapies and TALEN-based gene editing, Cellectis is projected to hit an average target price of $7.00, offering ...

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

If there is a strong suspicion of lymphocytic hypophysitis and there is no visual loss, then corticosteroid therapy is usually given as first-line management. It is important to measure IgG4 ...

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment ...

programmed T-cell therapies for the treatment of cancer and autoimmune diseases. The company’s lead product, AUCATZYL, ...